CLAIMS

1. Use of a fast-dispersing pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof in the manufacture of medicament in ~~A method of~~ treating migraine in a patient in need thereof~~, comprising orally administering to the patient a fast-dispersing pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof.~~, wherein said medicament is to be orally administered.

2. The use~~method~~ according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in migraine pain freedom within 2 hours of the time of administration.

3. The use~~method~~ according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in about 21.2% of patients achieving migraine pain freedom within 2 hours of the time of administration.

4. The ~~method~~ use according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in freedom from most bothersome symptoms within 2 hours of the time of administration.

5. The use~~method~~ according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in about 35.1% of patients achieving freedom from most bothersome symptoms within 2 hours of the time of administration.

~~6. The method according to Claim 5, wherein the most bothersome symptoms comprise photophobia, nausea, phonophobia, or a combination thereof.~~

6~~7~~. The use~~method~~ according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in pain relief within 90 minutes of the time of administration.

78. The use ~~method~~ according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in about 49.6% of patients achieving pain relief within 90 minutes of the time of administration.

89. The ~~method~~ use according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in achieving pain relief within 2 hours of the time of administration.

910. The use ~~method~~ according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in about 59.3% of patients achieving pain relief within 2 hours of the time of administration.

1011. The ~~method~~ use according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in sustained pain relief within 2 to 48 hours of the time of administration.

~~12. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 42.2% of patients achieving sustained pain relief within 2 to 48 hours of the time of administration.~~

1113. The ~~method~~ use according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in sustained pain freedom within 2 to 48 hours of the time of administration.

~~14. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 13.5% of patients achieving sustained pain freedom within 2 to 48 hours of the time of administration.~~

1215. The ~~method~~ use according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in reduced usage of rescue medication within 24 hours of the time of administration.

~~16. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 14.2% of patients using rescue medication within 24 hours of the time of administration.~~

13~~17~~. The ~~method~~ use according to Claim 1, wherein ~~administering~~ the pharmaceutical composition results in normal function within 2 hours of the time of administration.

~~18. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 38.1% of patients reporting normal function within 2 hours of the time of administration.~~

14~~19~~. The ~~method~~ use according to Claim 1, wherein the daily dose of rimegepant is about 75 mg.

15~~20~~. The ~~method~~ use according to Claim 1, wherein the pharmaceutical composition is to be administered to a patient up to 15 times in a 30-day period.

16~~21~~. The ~~method~~ use according to Claim 1, wherein the pharmaceutically acceptable salt or rimegepant is rimegepant hemisulfate.

17~~22~~. The ~~method~~ use according to Claim 1, wherein the daily dose of rimegepant hemisulfate is about 85.65 mg.

18~~23~~. The ~~method~~ use according to Claim 1, wherein the pharmaceutical composition further includes benzyl alcohol, eucalyptol, gelatin, limonene, mannitol, menthol, menthone, menthyl acetate, sucralose, vanillin, or a combination thereof.

19~~24~~. The use~~method~~ according to Claim 1, wherein about 1.3% or less of patients who received the pharmaceutical composition experience nausea.

2025. The ~~method~~ use according to Claim 1, wherein about 0.15% or less of patients who received the pharmaceutical composition experience hypersensitivity.

~~26. The method according to Claim 25, wherein the hypersensitivity comprises dyspnea, rash, or a combination thereof.~~